Gain confidence knowing your horse is getting everything they need with this complete, balanced formula
GLP-1 agonists have the potential to become some of the best selling drugs of all time Targeting very large and rapidly growing markets Potential differentiation in dual-acting mechanism, biased signaling, and oral delivery GLP-1/GIP dual agonists have demonstrated greater weight loss than GLP-1 mono-agonists Positive early clinical data Weight loss observed in early clinical trials of CT-388 appears to be lower than that of approved GLP-1 and GLP-1/GIP agonists Will need to demonstrate some level of clinical differentiation, or comparable clinical activity and lower cost, to garner significant revenue Late-stage trials in Type 2 Diabetes and obesity are very expensive Drugs will need to generate billions in annual sales to justify price paid Carmot Therapeutics was acquired by Roche for $2.7 billion in December 2023
Composition & Quality Assurance Each vial contains: 30mg Retatrutide peptide (lyophilized powder) Pharmaceutical-grade formulation Free from fillers and unnecessary additives All products undergo strict quality control testing to verify identity, purity, and performance
The indication reads moderate to severe obstructive sleep apnea in adults with obesity. It does not say for weight loss. It says for OSA. That single phrase is the entire reason this article exists
The conventional blend is almost always based on the no-DAC form, because its short kinetics match the pulse-like action of Ipamorelin
100 : 322S325S
